AWM
PACB icon

Accel Wealth Management’s Pacific Biosciences PACB Stock Holding History

Accel Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-195
Closed -$7K – 869
2021
Q2 		$7K Hold
195
– – ﹤0.01% 748
2021
Q1 		$6K Buy
195
+75
+63% +$2.63K ﹤0.01% 729
2020
Q4 		$3K Buy
+120
New +$2.04K ﹤0.01% 763

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Accel Wealth Management's PACB Position: Q3 2021 in Review

Accel Wealth Management sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 195 shares — an estimated $7K sold.

Accel Wealth Management first reported a position in PACB in Q4 2020 and held it in 3 quarters. The position peaked at $7K in Q2 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Accel Wealth Management reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Accel Wealth Management sold 195 Pacific Biosciences shares in Q3 2021, an estimated $7K.
  • Accel Wealth Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 3 quarters.
  • Accel Wealth Management's Pacific Biosciences position peaked at $7K in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Accel Wealth Management's 13F filing for Q3 2021, filed 4 Nov 2021.